ReviewFrontiers in genome editing2020
Targeted Gene Delivery: Where to Land.
Review in Frontiers in genome editing, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Gene therapy for liver diseases: methods, challenges and opportunities.Journal of nanobiotechnology · 2026Review
- A precision gene-engineered B cell medicine producing sustained levels of active factor IX for hemophilia B therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Human Genome Safe Harbor Sites: A Comprehensive Review of Criteria, Discovery, Features, and Applications.Cells · 2026Review
- Toward Safe and Effective Gene Therapy: Non-Viral Nanostructured Delivery Systems.International journal of nanomedicine · 2026Review
- A Xeno-Free Protocol for Rapid Differentiation of Human iPSC-Derived Microglia from the KOLF2.1J Reference Line.Bioengineering (Basel, Switzerland) · 2025Article
- A xeno-free protocol for rapid differentiation of human iPSC-derived microglia from the KOLF2.1J reference line.bioRxiv : the preprint server for biology · 2025Article
- Designer mammalian living materials through genetic engineering.Bioactive materials · 2025Review
- SHIP identifies genomic safe harbors in eukaryotic organisms using genomic general feature annotation.Scientific reports · 2025Article
- Expression of transgenic biotin ligases in inducible neuronal murine cell lines by integration into the mHipp11 gene locus.PloS one · 2025Article
- CRISPR-based functional genomics for schistosomes and related flatworms.Trends in parasitology · 2024Review
- Effect of genomic and cellular environments on gene expression noise.Genome biology · 2024Article
- Targeted insertion and reporter transgene activity at a gene safe harbor of the human blood fluke,Cell reports methods · 2023Article
- Genetic manipulation and targeted protein degradation in mammalian systems: practical considerations, tips and tricks for discovery research.FEBS open bio · 2023Review
- Precise homology-directed installation of large genomic edits in human cells with cleaving and nicking high-specificity Cas9 variants.Nucleic acids research · 2023Article
- High-capacity adenovector delivery of forced CRISPR-Cas9 heterodimers fosters precise chromosomal deletions in human cells.Molecular therapy. Nucleic acids · 2023Article
- Article
- Knockout of liver fluke granulin, Ov-grn-1, impedes malignant transformation during chronic infection with Opisthorchis viverrini.PLoS pathogens · 2022Article
- Large-scale genome editing based on high-capacity adenovectors and CRISPR-Cas9 nucleases rescues full-length dystrophin synthesis in DMD muscle cells.Nucleic acids research · 2022Article
- Establishment and characterization of a novel human induced pluripotent stem cell line stably expressing the iRFP720 reporter.Scientific reports · 2022Article
- Optimization of Genome Knock-In Method: Search for the Most Efficient Genome Regions for Transgene Expression in Plants.International journal of molecular sciences · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genome-editing technologies have the potential to correct most genetic defects involved in blood disorders. In contrast to mutation-specific editing, targeted gene insertion can correct most of the mutations affecting the same gene with a single therapeutic strategy (gene replacement) or provide novel functions to edited cells (gene addition). Targeting a selected genomic harbor can reduce insertional mutagenesis risk, while enabling the exploitation of endogenous promoters, or selected chromatin contexts, to achieve specific transgene expression levels/patterns and the modulation of disease-modifier genes. In this review, we will discuss targeted gene insertion and the advantages and limitations of different genomic harbors currently under investigation for various gene therapy applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.